APA (7th ed.) Citation

Ivashkin, V. T., Maslennikov, R. V., Vasilieva, E. V., Chipurik, M. L., Semikova, P. A., Semenets, V. V., & Russkova, T. A. Sarilumab is not Inferior to Tocilizumab in the Treatment of Cytokine Release Syndrome in COVID-19. Gastro LLC.

Chicago Style (17th ed.) Citation

Ivashkin, V. T., R. V. Maslennikov, E. V. Vasilieva, M. L. Chipurik, P. A. Semikova, V. V. Semenets, and T. A. Russkova. Sarilumab Is Not Inferior to Tocilizumab in the Treatment of Cytokine Release Syndrome in COVID-19. Gastro LLC.

MLA (9th ed.) Citation

Ivashkin, V. T., et al. Sarilumab Is Not Inferior to Tocilizumab in the Treatment of Cytokine Release Syndrome in COVID-19. Gastro LLC.